Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter's broad-spectrum anti-microbial vaccine in India and other low income ...

India's Bharat Biotech said on Tuesday it was studying if its Covaxin shot would work against variants of coronavirus such as Omicron, after the CEO of drugmaker Moderna warned that existing ...

SAO PAULO (Reuters) - Bharat Biotech has terminated a memorandum of understanding to sell its COVID-19 vaccine Covaxin to Brazil's Precisa Medicamentos, the ...

The vaccine, made by Bharat Biotech, is widely used in India. It has not been tested in the U.S., which has not authorized it for any age groups.

[1/2]Rupali Deshraj Nirmal, 16, reacts as she receives a dose of Bharat Biotech's COVID-19 vaccine, Covaxin, during a vaccination drive for children aged 15-18 in Mumbai, India, January 3, 2022.

Bharat Biotech will supply initial doses to be used in the U.S. upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the U.S.

Indian vaccine maker Bharat Biotech's nasal COVID-19 vaccine candidate has received regulatory approval for mid- to late-stage trials, the government's ministry of science and technology said in a ...

Bharat Biotech said the results found Covaxin provided 65.2% protection against the Delta variant, which was first detected in India and is the dominant variant in the country.

Bharat Biotech International Ltd., India’s home-grown vaccine developer, priced its coronavirus shots as much as double that of its local competitor, citing high manufacturing costs even as the ...

Shares of Ocugen Inc. soared 31.0% in premarket trading Wednesday, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 ...

Bharat Biotech maintains a 55% stake in any U.S. profits versus 45% for OCGN plus all ex-U.S. profits. It should be valued substantially higher than OCGN.